BNT162b2疫苗在实体瘤患者中的长期免疫原性
Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors.
作者信息
Waldhorn Ithai, Holland Roy, Goshen-Lago Tal, Benguigui Madeleine, Halberthal Michael, Shaked Yuval, Ben-Aharon Irit
机构信息
Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Rappaport Faculty of Medicine, Technion, Haifa, Israel.
出版信息
JAMA Oncol. 2022 Jun 1;8(6):1-2. doi: 10.1001/jamaoncol.2022.1467.
Abstract
This cohort study examines cellular and humoral pathways at 6 months after BNT162b2 COVID-19 vaccination in patients with cancer who were receiving active antineoplastic treatment.
摘要
这项队列研究在接受积极抗肿瘤治疗的癌症患者中，考察了BNT162b2型新冠疫苗接种6个月后的细胞和体液途径。
相似文献
1
Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors.BNT162b2疫苗在实体瘤患者中的长期免疫原性
JAMA Oncol. 2022 Jun 1;8(6):1-2. doi: 10.1001/jamaoncol.2022.1467.
2
Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis.异源免疫接种方案对 COVID-19 疫苗的免疫原性和反应原性：系统评价和网络荟萃分析。
Chin Med J (Engl). 2023 Jan 5;136(1):24-33. doi: 10.1097/CM9.0000000000002567.
3
The Long-Term Tolerability of BNT162b2 in Children and Adolescents (the CoVacU18 Study).BNT162b2在儿童和青少年中的长期耐受性（CoVacU18研究）
Dtsch Arztebl Int. 2025 May 16;122(10):257-263. doi: 10.3238/arztebl.m2025.0032.
4
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.癌症患者接种一剂与两剂新冠疫苗BNT162b2的安全性和免疫原性：一项前瞻性观察研究的中期分析
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
5
Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.COVID-19 mRNA 疫苗接种后的不良反应：心血管并发症、血栓形成和血小板减少症的系统评价。
Immun Inflamm Dis. 2023 Mar;11(3):e807. doi: 10.1002/iid3.807.
6
Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.不同 SARS-CoV-2 候选疫苗在非人灵长类动物中的免疫原性和保护效力比较。
Indian J Med Res. 2021;153(1 & 2):93-114. doi: 10.4103/ijmr.IJMR_4431_20.
7
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
8
Long-term Response to SARS-CoV-2 mRNA Vaccine in Adolescents.青少年对SARS-CoV-2 mRNA疫苗的长期反应
Pediatr Infect Dis J. 2025 Jun 1;44(6):550-556. doi: 10.1097/INF.0000000000004709. Epub 2025 Jan 28.
9
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.在有和没有先前 SARS-CoV-2 感染的人群中，COVID-19 mRNA 疫苗加强针接种后和 COVID-19 后心肌炎和心包炎的风险：在英国的一项自身对照病例系列分析。
PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun.
10
Comparison of BNT162b2 and mRNA1273 vaccines in solid organ transplant recipients: Post-Hoc analysis of a Japanese national prospective study.BNT162b2 与 mRNA-1273 疫苗在实体器官移植受者中的比较：日本全国前瞻性研究的事后分析。
Scand J Immunol. 2023 Oct;98(4):e13308. doi: 10.1111/sji.13308. Epub 2023 Jun 28.
引用本文的文献
1
Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022.在一个疫苗接种率较低的东欧国家保加利亚，对心血管、肿瘤或慢性肺部疾病患者在 COVID-19 背景下的全国范围分析：2020 年 3 月至 2022 年 4 月。
BMJ Open. 2023 Aug 2;13(8):e068431. doi: 10.1136/bmjopen-2022-068431.
本文引用的文献
1
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.T 细胞对 SARS-CoV-2 刺突蛋白的交叉识别可识别奥密克戎。
Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31.
2
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors.BNT162b2疫苗在实体瘤癌症患者中的六个月疗效和毒性情况
Cancer Discov. 2021 Oct;11(10):2430-2435. doi: 10.1158/2159-8290.CD-21-1072. Epub 2021 Sep 2.
3
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.血清学状态和 SARS-CoV-2 BNT162b2 疫苗在癌症治疗患者中的毒性作用。
JAMA Oncol. 2021 Oct 1;7(10):1507-1513. doi: 10.1001/jamaoncol.2021.2675.
4
Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer.化疗显著减少癌症患者的 B 细胞，但不减少 T 细胞和 NK 细胞。
Cancer Immunol Immunother. 2020 Jan;69(1):147-157. doi: 10.1007/s00262-019-02449-y. Epub 2020 Jan 3.
Zotero 插件